Download PDF
CC BY 4.0 · TH Open 2024; 08(01): e19-e30
DOI: 10.1055/a-2202-4296
Original Article

Anticoagulation-Associated Bleeding in Patients Screened for Atrial Fibrillation versus Usual Care—A Post Hoc Analysis from the LOOP Study

Emilie Katrine Kongebro 
1   Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
,
Søren Zöga Diederichsen
1   Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
,
Lucas Yixi Xing
1   Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
,
Ketil Jørgen Haugan
2   Department of Cardiology, Zealand University Hospital Roskilde, Roskilde, Denmark
,
Claus Graff
3   Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
,
Søren Højberg
4   Department of Cardiology, Bispebjerg Hospital, Copenhagen University Hospital, Copenhagen, Denmark
,
Morten S. Olesen
1   Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
5   Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
,
Derk Krieger
6   Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Healthcare City, Dubai, United Arab Emirates
7   Department of Neurology, Mediclinic Parkview Hospital, Al Barsha South, Dubai, United Arab Emirates
,
Axel Brandes
8   Department of Cardiology, Odense University Hospital, Odense, Denmark
9   Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense C, Denmark
10   Department of Cardiology, University Hospital of Southern Denmark—Esbjerg, Esbjerg, Denmark
,
Lars Køber
1   Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
11   Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
,
Jesper Hastrup Svendsen
1   Department of Cardiology, Copenhagen University Hospital—Rigshospitalet, Copenhagen, Denmark
11   Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
› Author Affiliations Funding The LOOP study was supported by The Innovation Fund Denmark (12-135225), The Research Foundation for the Capital Region of Denmark (no grant number), The Danish Heart Foundation (11-04-R83-A3363-22625), Aalborg University Talent Management Programme (no grant number), Arvid Nilssons Fond (no grant number), Skibsreder Per Henriksen, R. og Hustrus Fond (no grant number), Medtronic (no grant number), and the AFFECT-EU consortium which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 847770.
› Further Information
   Permissions and Reprints


Abstract

Background Atrial fibrillation (AF) prevalence is rising; however, data on the bleeding risks associated with the detection of subclinical AF are needed.

Objective Our objective was to determine the bleeding increment associated with implantable loop recorder (ILR) screening for subclinical AF and subsequent anticoagulation initiation compared with usual care.

Methods This post hoc study utilized LOOP trial data from 6,004 elderly patients with stroke risks randomized to either ILR (n = 1,503) or usual care (n = 4,503). The mean follow-up time was 64.5 months, and none were lost to follow-up. The primary exposure was the initiation of oral anticoagulation, and the main outcome was the risk of major bleeding events following initiation of oral anticoagulants (OACs), determined by time-dependent cox regression. Second, we investigated antithrombotic prescription patterns and major bleeding events after antiplatelet treatment and in subgroups.

Results OAC was initiated in 1,019 participants with a mean age (years) of 78.8 (± 4.67) in control versus 77.0 (± 4.84) in ILR, p < 0.0001. Altogether did 202 participants end or pause OAC treatment. Among AF patients (n = 910) had 40 (28%) completely ended OAC and 105 (72%) temporarily paused OAC during follow-up. Major bleeding events totaled 221 (3.7%). Forty-seven major bleeding events followed an OAC initiation in 1,019 participants (4.6%); 26 versus 21 events in the control and ILR groups, respectively. The hazard ratio (HR) for major bleeding after OAC initiation compared with before initiation was 2.08 (1.50–2.90) p < 0.0001 overall, 2.81 (1.82–4.34) p < 0.0001 for control and 1.32 (0.78–2.23) p = 0.31 for the ILR group (p = 0.07 for interaction). Antiplatelet treatment resulted in an overall adjusted HR of 1.3 (0.96–1.75) p = 0.09. For OAC users aged ≥75 years in the ILR group, the rate of major bleeding was 1.73 (0.92–2.96) compared with 0.84 (0.36–1.66) for an age <75 years, and the rate of the corresponding control subgroup aged ≥75 years was 2.20 (1.23–3.63) compared with 1.64 (0.82–2.93) for an age <75 years.

Conclusion The individual risk of major bleeding increased twofold after initiation of oral anticoagulation for all patients in this study. However, the patients screened for subclinical AF did not have a higher bleeding risk after initiation of anticoagulation compared with those in usual care.

Trial Registration: The LOOP study is registered at ClinicalTrials.gov, identifier: NCT020364 50

Keywords

major bleeding - subclinical atrial fibrillation - implantable loop recorder screening - oral anticoagulation

Supplementary Material



Publication History

Received: 26 June 2023

Accepted: 14 October 2023

Accepted Manuscript online:
01 November 2023

Article published online:
08 January 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
    Google Scholar
  • 2 van Rein N, Heide-Jørgensen U, Lijfering WM, Dekkers OM, Sørensen HT, Cannegieter SC. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation 2019; 139 (06) 775-786
    CrossrefPubMedGoogle Scholar
  • 3 Krijthe BP, Kunst A, Benjamin EJ. et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34 (35) 2746-2751
    CrossrefPubMedGoogle Scholar
  • 4 Steffel J, Collins R, Antz M. et al; External reviewers. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021; 23 (10) 1612-1676
    Google Scholar
  • 5 Hylek EM, Held C, Alexander JH. et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol 2014; 63 (20) 2141-2147
    PubMedGoogle Scholar
  • 6 Svendsen JH, Diederichsen SZ, Højberg S. et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial. Lancet 2021; 398 (10310): 1507-1516
    CrossrefPubMedGoogle Scholar
  • 7 Diederichsen SZ, Haugan KJ, Køber L. et al. Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): rationale and design of a large randomized controlled trial. Am Heart J 2017; 187: 122-132
    CrossrefPubMedGoogle Scholar
  • 8 Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3 (04) 692-694
    CrossrefPubMedGoogle Scholar
  • 9 Diederichsen SZ, Haugan KJ, Brandes A. et al. Natural history of subclinical atrial fibrillation detected by implanted loop recorders. J Am Coll Cardiol 2019; 74 (22) 2771-2781
    CrossrefPubMedGoogle Scholar
  • 10 Rivera-Caravaca JM, Roldán V, Esteve-Pastor MA. et al. Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. Thromb Haemost 2017; 117 (07) 1448-1454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Komen JJ, Heerdink ER, Klungel OH. et al. Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J Cardiovasc Pharmacother 2021; 7 (FI1): f72-f80
    CrossrefPubMedGoogle Scholar
  • 12 McNeil JJ, Nelson MR, Woods RL. et al; ASPREE Investigator Group. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med 2018; 379 (16) 1519-1528
    CrossrefPubMedGoogle Scholar
  • 13 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement. JAMA 2022; 327 (16) 1577-1584
    CrossrefPubMedGoogle Scholar
  • 14 Jachno KM, Heritier S, Woods RL. et al. Examining evidence of time-dependent treatment effects: an illustration using regression methods. Trials 2022; 23 (01) 857
    CrossrefPubMedGoogle Scholar
  • 15 Kirchhof P, Toennis T, Goette A. et al; NOAH-AFNET 6 Investigators. Anticoagulation with Edoxaban in patients with atrial high-rate episodes. N Engl J Med 2023; 389 (13) 1167-1179
    Google Scholar
  • 16 Hansen ML, Sørensen R, Clausen MT. et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170 (16) 1433-1441
    CrossrefPubMedGoogle Scholar
  • 17 Dalgaard F, Mulder H, Wojdyla DM. et al. Patients with atrial fibrillation taking nonsteroidal anti-inflammatory drugs and oral anticoagulants in the ARISTOTLE Trial. Circulation 2020; 141 (01) 10-20
    CrossrefPubMedGoogle Scholar
  • 18 Svennberg E, Friberg L, Frykman V, Al-Khalili F, Engdahl J, Rosenqvist M. Clinical outcomes in systematic screening for atrial fibrillation (STROKESTOP): a multicentre, parallel group, unmasked, randomised controlled trial. Lancet 2021; 398 (10310): 1498-1506
    CrossrefPubMedGoogle Scholar
  • 19 Lamberts M, Staerk L, Olesen JB. et al. Major bleeding complications and persistence with oral anticoagulation in non-valvular atrial fibrillation: contemporary findings in real-life Danish patients. J Am Heart Assoc 2017; 6 (02) e004517
    CrossrefPubMedGoogle Scholar
  • 20 Ding WY, Rivera-Caravaca JM, Marín F, Li G, Roldán V, Lip GYH. Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical-trial evidence. Br J Clin Pharmacol 2022; 88 (01) 282-289
    CrossrefPubMedGoogle Scholar
  • 21 Patti G, Lucerna M, Pecen L. et al. Thromboembolic risk, bleeding outcomes and effect of different antithrombotic strategies in very elderly patients with atrial fibrillation: a sub-analysis from the PREFER in AF (PREvention oF Thromboembolic Events-European Registry in Atrial Fibrillation). J Am Heart Assoc 2017; 6 (07) e005657
    CrossrefPubMedGoogle Scholar
  • 22 Choi SY, Kim MH, Lee KM. et al. Age-dependent anticoagulant therapy for atrial fibrillation patients with intermediate risk of ischemic stroke: a nationwide population-based study. Thromb Haemost 2021; 121 (09) 1151-1160 DOI: 10.1055/a-1336-0476.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Munir MB, Hlavacek P, Keshishian A. et al. Contemporary clinical and economic outcomes among oral anticoagulant treated and untreated elderly patients with atrial fibrillation: Insights from the United States Medicare database. PLoS One 2022; 17 (02) e0263903
    CrossrefPubMedGoogle Scholar
  • 24 Robards J. National population projections: 2020-based interim. 2022; ;(January): 1-16
    PubMedGoogle Scholar
  • 25 Statistics Denmark. News from Statistics Denmark—Population growth highest in the elderly population. 2021; (187) 2021-2022 https://www.dst.dk/en/Statistik/emner/borgere/befolkning/befolkningsfremskrivning
    PubMedGoogle Scholar
  • 26 Hermans ANL, Gawalko M, Dohmen L. et al. Mobile health solutions for atrial fibrillation detection and management: a systematic review. Clin Res Cardiol 2022; 111 (05) 479-491
    CrossrefPubMedGoogle Scholar
  • 27 Engdahl J, Rosenqvist M. Large-scale screening studies for atrial fibrillation—is it worth the effort?. J Intern Med 2021; 289 (04) 474-492
    CrossrefPubMedGoogle Scholar
  • 28 Lip GYH, Proietti M, Potpara T. et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace 2023; 25 (09) euad226
    CrossrefPubMedGoogle Scholar